Modelling the health impact and cost-effectiveness of lymphatic filariasis eradication under varying levels of mass drug administration scale-up and geographic coverage.
Identifieur interne : 000899 ( PubMed/Corpus ); précédent : 000898; suivant : 000900Modelling the health impact and cost-effectiveness of lymphatic filariasis eradication under varying levels of mass drug administration scale-up and geographic coverage.
Auteurs : Christopher M. Stone ; Randee Kastner ; Peter Steinmann ; Nakul Chitnis ; Marcel Tanner ; Fabrizio TediosiSource :
- BMJ global health [ 2059-7908 ] ; 2016.
Abstract
A global programme to eliminate lymphatic filariasis (GPELF) is underway, yet two key programmatic features are currently still lacking: (1) the extension of efforts to all lymphatic filariasis (LF) endemic countries, and (2) the expansion of geographic coverage of mass drug administration (MDA) within countries. For varying levels of scale-up of MDA, we assessed the health benefits and the incremental cost-effectiveness ratios (ICERs) associated with LF eradication, projected the potential savings due to decreased morbidity management needs, and estimated potential household productivity gains as a result of reduced LF-related morbidity.
DOI: 10.1136/bmjgh-2015-000021
PubMed: 28588916
Links to Exploration step
pubmed:28588916Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Modelling the health impact and cost-effectiveness of lymphatic filariasis eradication under varying levels of mass drug administration scale-up and geographic coverage.</title><author><name sortKey="Stone, Christopher M" sort="Stone, Christopher M" uniqKey="Stone C" first="Christopher M" last="Stone">Christopher M. Stone</name><affiliation><nlm:affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Kastner, Randee" sort="Kastner, Randee" uniqKey="Kastner R" first="Randee" last="Kastner">Randee Kastner</name><affiliation><nlm:affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Steinmann, Peter" sort="Steinmann, Peter" uniqKey="Steinmann P" first="Peter" last="Steinmann">Peter Steinmann</name><affiliation><nlm:affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Chitnis, Nakul" sort="Chitnis, Nakul" uniqKey="Chitnis N" first="Nakul" last="Chitnis">Nakul Chitnis</name><affiliation><nlm:affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Tanner, Marcel" sort="Tanner, Marcel" uniqKey="Tanner M" first="Marcel" last="Tanner">Marcel Tanner</name><affiliation><nlm:affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Tediosi, Fabrizio" sort="Tediosi, Fabrizio" uniqKey="Tediosi F" first="Fabrizio" last="Tediosi">Fabrizio Tediosi</name><affiliation><nlm:affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:28588916</idno><idno type="pmid">28588916</idno><idno type="doi">10.1136/bmjgh-2015-000021</idno><idno type="wicri:Area/PubMed/Corpus">000899</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000899</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Modelling the health impact and cost-effectiveness of lymphatic filariasis eradication under varying levels of mass drug administration scale-up and geographic coverage.</title><author><name sortKey="Stone, Christopher M" sort="Stone, Christopher M" uniqKey="Stone C" first="Christopher M" last="Stone">Christopher M. Stone</name><affiliation><nlm:affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Kastner, Randee" sort="Kastner, Randee" uniqKey="Kastner R" first="Randee" last="Kastner">Randee Kastner</name><affiliation><nlm:affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Steinmann, Peter" sort="Steinmann, Peter" uniqKey="Steinmann P" first="Peter" last="Steinmann">Peter Steinmann</name><affiliation><nlm:affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Chitnis, Nakul" sort="Chitnis, Nakul" uniqKey="Chitnis N" first="Nakul" last="Chitnis">Nakul Chitnis</name><affiliation><nlm:affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Tanner, Marcel" sort="Tanner, Marcel" uniqKey="Tanner M" first="Marcel" last="Tanner">Marcel Tanner</name><affiliation><nlm:affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Tediosi, Fabrizio" sort="Tediosi, Fabrizio" uniqKey="Tediosi F" first="Fabrizio" last="Tediosi">Fabrizio Tediosi</name><affiliation><nlm:affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland.</nlm:affiliation></affiliation></author></analytic><series><title level="j">BMJ global health</title><idno type="ISSN">2059-7908</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A global programme to eliminate lymphatic filariasis (GPELF) is underway, yet two key programmatic features are currently still lacking: (1) the extension of efforts to all lymphatic filariasis (LF) endemic countries, and (2) the expansion of geographic coverage of mass drug administration (MDA) within countries. For varying levels of scale-up of MDA, we assessed the health benefits and the incremental cost-effectiveness ratios (ICERs) associated with LF eradication, projected the potential savings due to decreased morbidity management needs, and estimated potential household productivity gains as a result of reduced LF-related morbidity.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">28588916</PMID><DateCreated><Year>2017</Year><Month>06</Month><Day>07</Day></DateCreated><DateRevised><Year>2017</Year><Month>08</Month><Day>16</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2059-7908</ISSN><JournalIssue CitedMedium="Print"><Volume>1</Volume><Issue>1</Issue><PubDate><Year>2016</Year><Month>Apr</Month></PubDate></JournalIssue><Title>BMJ global health</Title><ISOAbbreviation>BMJ Glob Health</ISOAbbreviation></Journal><ArticleTitle>Modelling the health impact and cost-effectiveness of lymphatic filariasis eradication under varying levels of mass drug administration scale-up and geographic coverage.</ArticleTitle><Pagination><MedlinePgn>e000021</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjgh-2015-000021</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">A global programme to eliminate lymphatic filariasis (GPELF) is underway, yet two key programmatic features are currently still lacking: (1) the extension of efforts to all lymphatic filariasis (LF) endemic countries, and (2) the expansion of geographic coverage of mass drug administration (MDA) within countries. For varying levels of scale-up of MDA, we assessed the health benefits and the incremental cost-effectiveness ratios (ICERs) associated with LF eradication, projected the potential savings due to decreased morbidity management needs, and estimated potential household productivity gains as a result of reduced LF-related morbidity.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We extended an LF transmission model to track hydrocele and lymphoedema incidence in order to obtain estimates of the disability adjusted life years (DALYs) averted due to scaling up MDA over a period of 50 years. We then estimated the ICERs and the cost-effectiveness acceptability curves associated with different rates of MDA scale-up. Health systems savings were estimated by considering the averted morbidity, treatment-seeking behaviour and morbidity management costs. Gains in worker productivity were estimated by multiplying estimated working days lost as a result of morbidity with country-specific per-worker agricultural wages.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Our projections indicate that a massive scaling-up of MDA could lead to 4.38 million incremental DALYs averted over a 50-year time horizon compared to a scenario which mirrors current efforts against LF. In comparison to maintaining the current rate of progress against LF, massive scaling-up of MDA-pursuing LF eradication as soon as possible-was most likely to be cost-effective above a willingness to pay threshold of US$71.5/DALY averted. Intensified MDA scale-up was also associated with lower ICERs. Furthermore, this could result in health systems savings up to US$483 million. Extending coverage to all endemic areas could generate additional economic benefits through gains in worker productivity between US$3.4 and US$14.4 billion.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In addition to ethical and political motivations for scaling-up MDA rapidly, this analysis provides economic support for increasing the intensity of MDA programmes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stone</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universität Basel, Basel, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Statistics, North Carolina State University, Raleigh, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kastner</LastName><ForeName>Randee</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universität Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steinmann</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universität Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chitnis</LastName><ForeName>Nakul</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universität Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanner</LastName><ForeName>Marcel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universität Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tediosi</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Swiss Tropical and Public Health Institute, Basel, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universität Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>04</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Glob Health</MedlineTA><NlmUniqueID>101685275</NlmUniqueID><ISSNLinking>2059-7908</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2008 Aug 06;3(8):e2874</RefSource><PMID Version="1">18716676</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trop Med Int Health. 2004 Aug;9(8):843-5</RefSource><PMID Version="1">15303987</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Acta Trop. 2000 Dec 1;77(3):287-94</RefSource><PMID Version="1">11114391</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Negl Trop Dis. 2010 Jun 01;4(6):e708</RefSource><PMID Version="1">20532228</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Microbiol Rev. 2000 Apr;13(2):207-22</RefSource><PMID Version="1">10755998</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Med. 2011 Jan 25;8(1):e1000412</RefSource><PMID Version="1">21311585</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Negl Trop Dis. 2014 Dec 11;8(12):e3393</RefSource><PMID Version="1">25501002</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Med Decis Making. 1990 Jul-Sep;10(3):212-4</RefSource><PMID Version="1">2115096</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Negl Trop Dis. 2014 Nov 20;8(11):e3319</RefSource><PMID Version="1">25412180</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trends Parasitol. 2004 Aug;20(8):347-51</RefSource><PMID Version="1">15246314</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2016 Feb 1;62(3):334-341</RefSource><PMID Version="1">26486704</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trop Med Int Health. 2006 May;11(5):718-28</RefSource><PMID Version="1">16640625</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Philos Trans R Soc Lond B Biol Sci. 2013 Jun 24;368(1623):20120144</RefSource><PMID Version="1">23798692</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2012 Dec 15;380(9859):2129-43</RefSource><PMID Version="1">23245605</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Negl Trop Dis. 2015 Oct 09;9(10):e0004147</RefSource><PMID Version="1">26451729</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2012 Dec 15;380(9859):2197-223</RefSource><PMID Version="1">23245608</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Negl Trop Dis. 2014 Dec 11;8(12):e3328</RefSource><PMID Version="1">25502758</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Negl Trop Dis. 2007 Nov 21;1(2):e128</RefSource><PMID Version="1">18060080</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2013 Aug 22;369(8):745-53</RefSource><PMID Version="1">23964936</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Popul Health Metr. 2012 Sep 12;10(1):19</RefSource><PMID Version="1">22967055</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Negl Trop Dis. 2013 Nov 07;7(11):e2446</RefSource><PMID Version="1">24244762</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Public Health. 2015 Apr;105(4):629-36</RefSource><PMID Version="1">25713967</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Microbiol Rev. 2002 Apr;15(2):223-46</RefSource><PMID Version="1">11932231</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2008 Aug 13;3(8):e2936</RefSource><PMID Version="1">18698350</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Epidemiol Infect. 2000 Jun;124(3):529-41</RefSource><PMID Version="1">10982078</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2015 Jun 12;10(6):e0130603</RefSource><PMID Version="1">26070135</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2010 Nov 6;376(9752):1604-15</RefSource><PMID Version="1">21035839</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacoeconomics. 2009;27(11):903-17</RefSource><PMID Version="1">19888791</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trop Geogr Med. 1980 Sep;32(3):259-64</RefSource><PMID Version="1">7210162</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2015 May 07;10(5):e0123853</RefSource><PMID Version="1">25950443</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Negl Trop Dis. 2008 Oct 08;2(10):e317</RefSource><PMID Version="1">18841205</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2007 Apr 21;369(9570):1363-71</RefSource><PMID Version="1">17448822</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2009 Jun 27;373(9682):2192-3</RefSource><PMID Version="1">19582890</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Acta Trop. 2000 Sep 18;76(2):197-9</RefSource><PMID Version="1">10936580</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Vaccine. 2011 Dec 30;29 Suppl 4:D70-3</RefSource><PMID Version="1">22188936</PMID></CommentsCorrections></CommentsCorrectionsList><CoiStatement>Competing interests: MT serves as board member for DNDi, and serves on the scientific advisory board of the Novartis Institute for Tropical Diseases.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>12</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>01</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>01</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>6</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>6</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>4</Month><Day>6</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28588916</ArticleId><ArticleId IdType="doi">10.1136/bmjgh-2015-000021</ArticleId><ArticleId IdType="pii">bmjgh-2015-000021</ArticleId><ArticleId IdType="pmc">PMC5321305</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000899 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000899 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:28588916
|texte= Modelling the health impact and cost-effectiveness of lymphatic filariasis eradication under varying levels of mass drug administration scale-up and geographic coverage.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:28588916" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |